BIOVENTUS INC - A (BVS) Stock News
NASDAQ:BVS - Nasdaq - US09075A1088 - Common Stock - Currency: USD
BVS Latest News, Press Relases and Analysis
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates
Bioventus (BVS) delivered earnings and revenue surprises of 33.33% and 2.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: NOTV
Bioventus Reports First Quarter Financial Results
Q1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0%First quarter net loss was $0.04 per share compared to a loss of $0.08...
Bioventus Reports First Quarter Financial Results
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now
Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Solventum Stock Earns 81 RS Rating
Solventum stock saw a positive improvement to its Relative Strength Rating on Tuesday, with an upgrade from 78 to 81.
BVS Stock Earnings: Bioventus Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bioventus (NASDAQ:BVS) just reported results for the second quarter of 2024.Bio...
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash...
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active...
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active...
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
Bioventus Reports Third Quarter Financial Results
Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* GrowthQ3 Gross Margin Expanded 200 bpsQ3 Cash from Operations of $10.3...
Bioventus Reports Third Quarter Financial Results
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active...
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
DURHAM, N.C., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active...
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that...